MedDataX Logo

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

NCT ID: NCT05945524

Last Updated: 2025-04-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-28

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098

Hematological Malignancies
ACTIVE_NOT_RECRUITING PHASE2

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222

Multiple Myeloma
RECRUITING PHASE3

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025

Multiple Myeloma
ACTIVE_NOT_RECRUITING PHASE2

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146

Multiple Myeloma
ACTIVE_NOT_RECRUITING PHASE1

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

NCT05572229

Multiple Myeloma
RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Analysis of bone marrow

Analysis of bone marrow in patients initiated treatment by Teclistamab for 18 cycles

Group Type EXPERIMENTAL

Bone marrow sampling

Intervention Type OTHER

Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bone marrow sampling

Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* With multiple myeloma
* Who receive Teclistamab
* Consent form signed

Exclusion Criteria

* Patient under legal protection
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Toulouse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hervé AVET LOISEAU, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU d'Amiens

Amiens, France, France

Site Status RECRUITING

CHU de Caen

Caen, France, France

Site Status RECRUITING

Polyclinique du Parc Drevon

Dijon, France, France

Site Status RECRUITING

CH Annecy Genevois

Epagny Metz- Tessy, France, France

Site Status RECRUITING

CHU de Lille

Lille, France, France

Site Status RECRUITING

Centre Léon Bérard

Lyon, France, France

Site Status RECRUITING

CHU de Montpellier

Montpellier, France, France

Site Status RECRUITING

Hôpital Saint-Louis

Paris, France, France

Site Status RECRUITING

Hôpital Saint-Antoine

Paris, France, France

Site Status RECRUITING

Hôpital Necker

Paris, France, France

Site Status RECRUITING

CHU de Bordeaux

Pessac, France, France

Site Status RECRUITING

CHU de Lyon

Pierre-Bénite, France, France

Site Status RECRUITING

CHU de Poitiers

Poitiers, France, France

Site Status RECRUITING

CHU de Rennes

Rennes, France, France

Site Status RECRUITING

CH Saint-Etienne

Saint-Priest-en-Jarez, France, France

Site Status RECRUITING

CHU de Toulouse

Toulouse, France, France

Site Status RECRUITING

CHU de Tours

Tours, France, France

Site Status RECRUITING

CHRU Nancy

Vandœuvre-lès-Nancy, France, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hervé AVET LOISEAU, MD, PhD

Role: CONTACT

[email protected]
+33 531 156 142 ext. 33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lydia MONTES, MD

Role: primary

[email protected]
0222455482 ext. 33

Margaret MACRO, MD, PhD

Role: primary

[email protected]
0231272633 ext. 33

Ingrid LAFON, MD

Role: primary

[email protected]
0380294506 ext. 33

Frédérique ORSINI PIOCELLE, MD

Role: primary

[email protected]
0450636144 ext. 33

Salomon MANIER, MD

Role: primary

[email protected]
0320444292 ext. 33

Philippe REY, MD

Role: primary

[email protected]
0478782737 ext. 33

Laure VINCENT, MD

Role: primary

[email protected]
0467338362 ext. 33

Bertrand ARNULF, MD, PhD

Role: primary

[email protected]
0142499695 ext. 33

Mohamad MOTHY, MD

Role: primary

[email protected]
0149282620 ext. 33

Laurent FRENZEL, MD

Role: primary

[email protected]
0144495292 ext. 33

Cyrille HULIN, MD

Role: primary

[email protected]
0557623372 ext. 33

Lionel KARLIN, MD

Role: primary

[email protected]
0448864309 ext. 33

Xavier LELEU, MD, PhD

Role: primary

[email protected]
0549444201 ext. 33

Olivier DECAUX, MD, PhD

Role: primary

[email protected]
0299287692 ext. 33

Emilie CHALAYER, MD

Role: primary

[email protected]
0477917061 ext. 33

Aurore PERROT, MD, PhD

Role: primary

[email protected]
0531156490 ext. 33

Thomas CHALOPIN, MD

Role: primary

[email protected]
0247473712 ext. 33

Caroline JACQUET, MD

Role: primary

[email protected]
0383155249 ext. 33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC31/23/0278

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991 ACTIVE_NOT_RECRUITING PHASE1
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515 ACTIVE_NOT_RECRUITING PHASE3
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
NCT05338775 ACTIVE_NOT_RECRUITING PHASE1
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
NCT06062537 ACTIVE_NOT_RECRUITING
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135 RECRUITING PHASE2
Plan Development for Giving Teclistamab in the Outpatient Setting
NCT06251076 RECRUITING PHASE4
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
NCT03145181 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
NCT04108195 ACTIVE_NOT_RECRUITING PHASE1
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
NCT05849610 ACTIVE_NOT_RECRUITING PHASE2
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748 COMPLETED PHASE2
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169 ACTIVE_NOT_RECRUITING PHASE3
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
NCT03848676 COMPLETED
Limited-duration Teclistamab
NCT05932680 RECRUITING PHASE2
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain
NCT03602755 COMPLETED
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320 ACTIVE_NOT_RECRUITING PHASE3
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
NCT07105059 RECRUITING PHASE1
Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma
NCT03487133 COMPLETED PHASE2
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05050097 ACTIVE_NOT_RECRUITING PHASE1
Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
NCT03993912 ACTIVE_NOT_RECRUITING PHASE3
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
NCT02312258 COMPLETED PHASE3
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
NCT00532675 COMPLETED PHASE1
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
NCT01094548 COMPLETED PHASE2
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
NCT01058434 COMPLETED PHASE2
Frontline Therapy in de Novo Multiple Myeloma Patients Under 65
NCT01206205 COMPLETED PHASE2